title: Opportunities for pharmacotherapy at the intersection of metabolic syndrome and hemostasis.
abstract: Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.
authors.affiliation: Eli Lilly and Company, Lilly Corporate Center, DC0520, Indianapolis, IN 46285, USA. laura_michael@lilly.com
authors.forename: Laura F
authors.initials: LF
authors.lastname: Michael
authors.forename: Veena
authors.initials: V
authors.lastname: Rao
authors.forename: Patrick
authors.initials: P
authors.lastname: McCollam
authors.forename: Mark C
authors.initials: MC
authors.lastname: Kowala
authors.forename: John
authors.initials: J
authors.lastname: Wetterau
mesh_terms: D000818:Animals; D006487:Hemostasis; D006801:Humans; D024821:Metabolic Syndrome / Q000097:blood* / Q000453:epidemiology / Q000628:therapy; D013927:Thrombosis / Q000503:physiopathology